Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Onconova, STA Ink Exclusive License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Onconova, STA Ink Exclusive License Agreement

STA gains exclusive rights to commercialize rigosertib in Australia and New Zealand

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Onconova Therapeutics, Inc., a biopharmaceutical company discovering and developing novel cancer treatments with a focus on myelodysplastic syndromes (MDS), has entered into a Distribution, License, and Supply Agreement granting Specialized Therapeutics Asia (STA) exclusive rights to commercialize rigosertib in Australia and New Zealand. Onconova may be entitled to receive clinical, regulatory, and sales-based milestones of as much as $30.4 million and royalties on net sales.

“We are pleased to partner with Specialised Therapeutics Asia, which has a strong track record of commercializing new products in oncology and hematology across Australia and New Zealand,” said Dr. Steven Fruchtman, president and chief executive officer of Onconova. “We look forward to working together and, pending a successful readout of the ongoing INSPIRE Trial, potentially providing rigosertib as a new therapeutic option for patients diagnosed with MDS.”

STA chief executive officer, Mr. Carlo Montagner, said that “patients with high-risk MDS have limited treatment options following currently available first-line treatment. There is no currently approved treatment following failure of standard chemotherapy with hypomethylating agents. Patients are left with the option of entering clinical trials, if available, or supportive care,” he said. “If approved, rigosertib would address an unmet medical need and may be a valuable inclusion to the STA therapeutic portfolio. We are delighted to enter into this collaboration with Onconova and look forward to the results of the ongoing phase 3 INSPIRE Trial of intravenous (IV) rigosertib.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters